<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00936026</url>
  </required_header>
  <id_info>
    <org_study_id>MRZ 92579/TI/1002</org_study_id>
    <nct_id>NCT00936026</nct_id>
  </id_info>
  <brief_title>Open, Single Center, Three Periods, Fixed Sequence Design Study on the Effects of Clopidogrel Co-administration on the Pharmacokinetics of Neramexane</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merz Pharmaceuticals GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merz Pharmaceuticals GmbH</source>
  <brief_summary>
    <textblock>
      Primary:&#xD;
&#xD;
      To assess the effects of CYP2B6 inhibition by repeated dose Clopidogrel (75 mg/day)&#xD;
      co-administration on the single-dose pharmacokinetics of Neramexane&#xD;
&#xD;
      Secondary:&#xD;
&#xD;
      To assess safety and tolerability of Neramexane single dose treatment alone and&#xD;
      co-administration of a Neramexane single-dose with a Clopidogrel repeated dose treatment&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Healthy Subjects</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neramexane</intervention_name>
    <description>Drug-Drug Interaction Study</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adult subject of white origin, who is able to read, to write and fully&#xD;
             understand German language&#xD;
&#xD;
          2. Aged 18 to 45 years&#xD;
&#xD;
          3. BMI of 18-28 kg/m2 and a body weight of 50-90 kg&#xD;
&#xD;
          4. Willing and able to provide written informed consent after having been informed of the&#xD;
             requirements and the restrictions of the study. Female subjects of childbearing&#xD;
             potential must agree to use a highly effective method of birth control defined as&#xD;
             those which result in a low failure rate (i.e. less than 1 % per year) when used&#xD;
             consistently and correctly such as sexual abstinence, vasectomised partner, non&#xD;
             hormonal IUDs, double barrier methods, for instance, e.g. condom and spermicide cream.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of clinically relevant allergy or known hypersensitivity to Neramexane/&#xD;
             Memantine/Amantadine and their derivatives&#xD;
&#xD;
          2. History of clinically relevant allergy or known hypersensitivity to Clopidogrel&#xD;
&#xD;
          3. Exposure to another investigational agent within the last two months before Day 1 of&#xD;
             Period 1&#xD;
&#xD;
          4. History of clinically relevant allergy or known hypersensitivity to any inactive&#xD;
             ingredient in any of the used investigational products or the metabolic inhibitor&#xD;
&#xD;
          5. Lactating or pregnant females or females planning to become pregnant during study&#xD;
             conduct or within 2 months after end of study&#xD;
&#xD;
          6. Any contraindications which are indicated in the topically valid SPC for Plavix®:&#xD;
             severe hepatic impairment; active pathological bleeding such as peptic ulcer or&#xD;
             intracranial hemorrhage&#xD;
&#xD;
             Lack of suitability for the trial:&#xD;
&#xD;
          7. Any evidence of a significant cardiovascular, pulmonary, renal, hepatic,&#xD;
             gastrointestinal, endocrinological, metabolic or other disease at screening&#xD;
&#xD;
          8. History of malignancy&#xD;
&#xD;
          9. Any clinically relevant deviation in clinical or laboratory assessment&#xD;
&#xD;
         10. ECG abnormalities of clinical relevance, in particular abnormal prolongations of&#xD;
             QT/QTc-interval (i.e. QTc ≥ 450 ms, PQ ≥ 220 ms)&#xD;
&#xD;
         11. Systolic blood pressure &lt;95 mmHg or &gt;150 mmHg or diastolic blood pressure &lt; 50 mmHg or&#xD;
             &gt;90 mmHg in supine position&#xD;
&#xD;
         12. Pulse rate &lt;45 or &gt;100 beats per minute&#xD;
&#xD;
         13. Chronic or acute clinically relevant infections&#xD;
&#xD;
         14. Acute or chronic disease, especially psychiatric or neurologic disorders&#xD;
&#xD;
         15. History of alcohol or drug dependence&#xD;
&#xD;
         16. Alcohol consumption averaging more than 40 g for male and more than 20 g for female&#xD;
             subjects daily within the last year&#xD;
&#xD;
         17. Regular caffeine consumption averaging more than 1 L of coffee and/or tea daily or&#xD;
             more than 1 L of caffeine-containing lemonades per day within the last year&#xD;
&#xD;
         18. Disorders or surgery of the gastrointestinal tract which may interfere with drug&#xD;
             absorption or may otherwise influence the pharmacokinetics of the investigational&#xD;
             medicinal products (e.g. cholecystectomy, ulcus, etc.)&#xD;
&#xD;
         19. Anticipated donation of spermatocytes or oocytes for medically assisted reproduction&#xD;
             techniques [ART] within two months after the last dose of the present study&#xD;
&#xD;
         20. Use of any prescribed medication for four weeks prior to the first administration of&#xD;
             IMP.&#xD;
&#xD;
               -  Regular use of over-the-counter drugs in the 4 weeks prior to the first&#xD;
                  administration of the IMP&#xD;
&#xD;
               -  Occasional use of OTC drugs (except paracetamol, maximum 1 g/day) within the 2&#xD;
                  weeks prior to the first administration of the IMP.&#xD;
&#xD;
               -  Stable intake of thyroid hormone substitution will be allowed.&#xD;
&#xD;
         21. Use of any food, food supplement or medication known to induce or inhibit CYP3A4 or&#xD;
             other cytochrome P450 enzymes within two weeks preceding the start of the study (Day&#xD;
             1), e.g. grapefruit, St. John's wort&#xD;
&#xD;
         22. Female subjects who employed any form of hormonal contraception within 2 months prior&#xD;
             to study Day 1 (e.g. oral contraceptives, hormone releasing intrauterine contraceptive&#xD;
             devices [IUDs], etc.)&#xD;
&#xD;
         23. Consumption of xanthine derivates (including caffeine) within two days prior to Day 1&#xD;
&#xD;
         24. Smoker and user of snuff, nicotine replacement and chewing tobacco&#xD;
&#xD;
         25. Previous enrolment into the clinical phase of the current study&#xD;
&#xD;
         26. Positive results in any of the serology tests&#xD;
&#xD;
         27. Blood donation more than 450 mL within 60 days prior to Day 1&#xD;
&#xD;
         28. Positive pregnancy test, if female&#xD;
&#xD;
         29. Positive drug screen or alcohol test&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>AAIPharma Deutschland gmbH &amp; Co. KG</name>
      <address>
        <city>Neu Ulm</city>
        <state>Bayern</state>
        <zip>89231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>July 8, 2009</study_first_submitted>
  <study_first_submitted_qc>July 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2009</study_first_posted>
  <last_update_submitted>February 7, 2011</last_update_submitted>
  <last_update_submitted_qc>February 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. med. Margarete Müller</name_title>
    <organization>AAIPharma Deutschland gmbH &amp; Co. KG</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

